Although not new, VITT emerged as a new disease after the adenovirus vector-based Oxford-AstraZeneca vaccine
2021.
"An unusually virulent blood autoantibody directed against the protein term platelet factor 4 (or PF4)" was found to be the cause of VITT.
In separate research in 2023, scientists in Canada, North America, Germany, and Italy described a nearly identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Now in a new research, Flinders University in Australia and other international experts found that PF4 antibodies in both adenovirus infection-associated VITT and classic adenoviral vector VITT share the same molecular fingerprint, or signature.
"Indeed, the pathways of lethal antibody production in these disorders should be almost identical and have similar genetic risk factors," said Flinders Professor Tu Gordon.
The researcher said that "The findings have important clinical implications in that the lessons learned from VITT apply to rare cases of blood clots following adenovirus (a common cold) infection, as well as implications for vaccine development Are".The same team "cracked the molecular code of PF antibodies and identified a genetic risk factor" in a 2022 study.
Their new findings, published in the New England Journal of Medicine, also have important implications for improving vaccine safety.
The research comes after AstraZeneca "admitted in a legal document submitted to the High Court in February that its Covid vaccine 'can cause thrombotic thrombocytopenic syndrome (TTS) in very rare cases.'"
TTS is a rare side effect that can cause blood clots and low platelet counts in people. It has been linked to at least 81 deaths as well as hundreds of serious injuries in Britain.The company has also voluntarily withdrawn the "marketing authorization" of its Covid vaccine from Europe and other global markets.
2021.
"An unusually virulent blood autoantibody directed against the protein term platelet factor 4 (or PF4)" was found to be the cause of VITT.
In separate research in 2023, scientists in Canada, North America, Germany, and Italy described a nearly identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Now in a new research, Flinders University in Australia and other international experts found that PF4 antibodies in both adenovirus infection-associated VITT and classic adenoviral vector VITT share the same molecular fingerprint, or signature.
"Indeed, the pathways of lethal antibody production in these disorders should be almost identical and have similar genetic risk factors," said Flinders Professor Tu Gordon.
The researcher said that "The findings have important clinical implications in that the lessons learned from VITT apply to rare cases of blood clots following adenovirus (a common cold) infection, as well as implications for vaccine development Are".The same team "cracked the molecular code of PF antibodies and identified a genetic risk factor" in a 2022 study.
Their new findings, published in the New England Journal of Medicine, also have important implications for improving vaccine safety.
The research comes after AstraZeneca "admitted in a legal document submitted to the High Court in February that its Covid vaccine 'can cause thrombotic thrombocytopenic syndrome (TTS) in very rare cases.'"
TTS is a rare side effect that can cause blood clots and low platelet counts in people. It has been linked to at least 81 deaths as well as hundreds of serious injuries in Britain.The company has also voluntarily withdrawn the "marketing authorization" of its Covid vaccine from Europe and other global markets.
